This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Croci, S. Articles by Lollini, P.-L. Search for Related Content PubMed PubMed Citation Articles by Croci, S. Articles by Lollini, P.-L.

Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells

¹ Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy; ² Istituti Ortopedici Rizzoli, Bologna, Italy; ³ Section of Pediatric Hemato-Oncology, Department of Pediatrics, University of Padua, Padua, Italy; and ⁴ FibroGen Inc., South San Francisco, California

Connective tissue growth factor (CTGF/CCN2), a cysteine-rich protein of the CCN (Cyr61, CTGF, Nov) family of genes, emerged from a microarray screen of genes expressed by human rhabdomyosarcoma cells. Rhabdomyosarcoma is a soft tissue sarcoma of childhood deriving from skeletal muscle cells. In this study, we investigated the role of CTGF in rhabdomyosarcoma. Human rhabdomyosarcoma cells of the embryonal (RD/12, RD/18, CCA) and the alveolar histotype (RMZ-RC2, SJ-RH4, SJ-RH30), rhabdomyosarcoma tumor specimens, and normal skeletal muscle cells expressed CTGF. To determine the function of CTGF, we treated rhabdomyosarcoma cells with a CTGF antisense oligonucleotide or with a CTGF small interfering RNA (siRNA). Both treatments inhibited rhabdomyosarcoma cell growth, suggesting the existence of a new autocrine loop based on CTGF. CTGF antisense oligonucleotide-mediated growth inhibition was specifically due to a significant increase in apoptosis, whereas cell proliferation was unchanged. CTGF antisense oligonucleotide induced a strong decrease in the level of myogenic differentiation of rhabdomyosarcoma cells, whereas the addition of recombinant CTGF significantly increased the proportion of myosin-positive cells. CTGF emerges as a survival and differentiation factor and could be a new therapeutic target in human rhabdomyosarcoma.

This article has been cited by other articles:

				A. Dessein, C. Chevillard, V. Arnaud, X. Hou, A. A. Hamdoun, H. Dessein, H. He, S. A. Abdelmaboud, X. Luo, J. Li, et al. Variants of CTGF are associated with hepatic fibrosis in Chinese, Sudanese, and Brazilians infected with Schistosomes J. Exp. Med., October 26, 2009; 206(11): 2321 - 2328. [Abstract] [Full Text] [PDF]

				L. Ying, A. Lau, C. M. Alvira, R. West, G. M. Cann, B. Zhou, C. Kinnear, E. Jan, P. Sarnow, M. Van de Rijn, et al. LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor J. Cell Sci., May 1, 2009; 122(9): 1441 - 1451. [Abstract] [Full Text] [PDF]

				M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, and M.-L. Kuo Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1 Cancer Res., April 15, 2009; 69(8): 3482 - 3491. [Abstract] [Full Text] [PDF]

				Y. Sakai, T.A. Balam, S. Kuroda, N. Tamamura, T. Fukunaga, M. Takigawa, and T. Takano-Yamamoto CTGF and Apoptosis in Mouse Osteocytes Induced by Tooth Movement Journal of Dental Research, April 1, 2009; 88(4): 345 - 350. [Abstract] [Full Text] [PDF]

				P. Nanni, G. Nicoletti, A. Palladini, A. Astolfi, P. Rinella, S. Croci, L. Landuzzi, G. Monduzzi, V. Stivani, A. Antognoli, et al. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4 Mol. Cancer Ther., April 1, 2009; 8(4): 754 - 761. [Abstract] [Full Text] [PDF]

				K. L. Bennewith, X. Huang, C. M. Ham, E. E. Graves, J. T. Erler, N. Kambham, J. Feazell, G. P. Yang, A. Koong, and A. J. Giaccia The Role of Tumor Cell-Derived Connective Tissue Growth Factor (CTGF/CCN2) in Pancreatic Tumor Growth Cancer Res., February 1, 2009; 69(3): 775 - 784. [Abstract] [Full Text] [PDF]

				T.-W. Tan, W.-H. Yang, Y.-T. Lin, S.-F. Hsu, T.-M. Li, S.-T. Kao, W.-C. Chen, Y.-C. Fong, and C.-H. Tang Cyr61 increases migration and MMP-13 expression via {alpha}v{beta}3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells Carcinogenesis, February 1, 2009; 30(2): 258 - 268. [Abstract] [Full Text] [PDF]

				M. Doghman, M. Arhatte, H. Thibout, G. Rodrigues, J. De Moura, S. Grosso, A. N. West, M. Laurent, J.-C. Mas, A. Bongain, et al. Nephroblastoma Overexpressed/Cysteine-Rich Protein 61/Connective Tissue Growth Factor/Nephroblastoma Overexpressed Gene-3 (NOV/CCN3), a Selective Adrenocortical Cell Proapoptotic Factor, Is Down-Regulated in Childhood Adrenocortical Tumors J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3253 - 3260. [Abstract] [Full Text] [PDF]

				N. Dornhofer, S. Spong, K. Bennewith, A. Salim, S. Klaus, N. Kambham, C. Wong, F. Kaper, P. Sutphin, R. Nacalumi, et al. Connective Tissue Growth Factor-Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor Growth and Metastasis Cancer Res., June 1, 2006; 66(11): 5816 - 5827. [Abstract] [Full Text] [PDF]

				T. Aikawa, J. Gunn, S. M. Spong, S. J. Klaus, and M. Korc Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1108 - 1116. [Abstract] [Full Text] [PDF]

				M.-T. Lin, C.-Y. Zuon, C.-C. Chang, S.-T. Chen, C.-P. Chen, B.-R. Lin, M.-Y. Wang, Y.-M. Jeng, K.-J. Chang, P.-H. Lee, et al. Cyr61 Induces Gastric Cancer Cell Motility/Invasion via Activation of the Integrin/Nuclear Factor-{kappa}B/Cyclooxygenase-2 Signaling Pathway Clin. Cancer Res., August 15, 2005; 11(16): 5809 - 5820. [Abstract] [Full Text] [PDF]